Prellis is re-shaping drug development with responsive human tissues, starting with the Human Immune System. techcrunch.com/2021/12/15/pre…

Looking forward to seeing all of you at BIOS and sharing our fully in vitro human lymph node technology platform EXIS.

Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb Bristol Myers Squibb using the EXIS platform for high affinity human antibody discovery. businesswire.com/news/home/2022…

Access to human immune system pre #PhaseI is unprecedented in therapeutic development & the possibilities for development are endless. The capacity to screen therapeutics is just one of the applications of the EXIS platform. Enjoy some data revisiting TGN1412, this time in vitro

Join us this Friday at 12pm PT for Dr. David Schaffer's #TissueEngineering Journal Club #webinar presentation, "Molecular Elucidation and #Engineering of #StemCell Fate Decisions." Register at bit.ly/3uEJTy0. #Biotech #STEM #Seminar QB3-Berkeley UC Berkeley

Had a fantastic time with the Cantos team discussing our human #antibody platform derived from first in class lymph node organoids — and how application of our holographic laser printing has opened the door to a multitude of human tissue applications/products.

Delighted to partner with Sanofi, here at Prellis Biologics we are recreating the human immune response and breaking tolerance to human antigens in the EXIS platform allowing us to rapidly identify an expansive set of high-quality antibodies businesswire.com/news/home/2022…

Celesta Capital Founder Spotlight: Melanie Matheu, PhD, founder & CEO of Prellis Biologics, shares her path to entrepreneurship, and how she seeks inspiration: celesta.vc/insights/q-a-w…

While I applaud the efforts in silico to solve problems in drug discovery, no system does it better than the immune system: we make our own drugs. Access to human immunobiology is a direct line to therapeutics, and distinctly advantageous starting point for in silico platforms.

In 2022 an old man living in the past launched a surprise attack against a group whose independence he'd long resented. Unified by his aggression, they turned out to be much more powerful than he'd anticipated, and he soon regretted his decision. Also, Putin invaded Ukraine.

Phenomenal #BIO2022 for the Prellis Biologics team!

If you could bio-print any tissue in the world which one would you start with? The question was answered by the market - whichever one moves the needle the most in the largest possible markets. Hence the EXIS platform was born. sosv.com/the-loneliness…

Delighted to announce Mike Nohaile joining the Prellis team as CEO and the close of a $35M series C raise. businesswire.com/news/home/2022…

High quality decision making while reducing non-productive interactions is critical. Part of the reason I'm slightly allergic to email for use as anything other than a filing system. If we’re all so busy, why isn’t anything getting done? mck.co/3zK2pVV McKinsey & Company

Excellent goal. I believe that in the next 10 years if we combine diagnostics, targeted therapeutics, and an improved understanding of disease progression we will reach a place where #cancer becomes a live with and monitor disease, no longer a death sentence.

Congratulations Carolyn Bertozzi having worked directly with this chemistry and one of your prior post-docs, this is well deserved. Works like magic. Nobel Prize in Chemistry Is Awarded to 3 Scientists for Work ‘Snapping Molecules Together’ nytimes.com/2022/10/05/sci…

I am leaving Twitter now. Thank you jack for a wonderful app that connected so many and provided a phenomenal world forum. I've had my account since early 2008. Looking forward to the next social platform.

After nearly two years off of X I have decided to re-join. I am still not a fan of attacks on public health officials during the first pandemic in 100 years & will be primarily using Threads, but too many of my colleagues are here and there are some big announcements coming up.

Excited to join forces with Kayj Shannon to launch a new company tackling the multi-billion-dollar markets of donor derived therapeutics. Leveraging Prellis Biologics tech we are excited to usher in a new era of drug manufacturing. Read more about our founding story here: